Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck: Correlation with p53 status, inducible nitric oxide synthase activity, and angiogenesis

Cancer

Volumn 95, Issue 9, 2002, Pages 1902-1910

  Franchi, Alessandro ^a   Santucci, Marco ^a   Masini, Emanuela ^a   Sardi, Iacopo ^a   Paglierani, Milena ^a   Gallo, Oreste ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Head and neck; Matrix metalloproteinases; Nitric oxide; p53; Squamous cell carcinoma

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN P53;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CYCLIC GMP; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICROCIRCULATION; MOUTH NEOPLASMS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OROPHARYNGEAL NEOPLASMS;

EID: 0036839665     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10916     Document Type: Article

References (44)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:53-364.
2. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260-1270.
3. Shima I, Sasaguri Y, Kusukawa J, et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer. 1992;70:2747-2753.
4. Kusukawa J, Sasaguri Y, Shima I, Kameyama T, Morimatsu M. Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study. Am J Clin Pathol. 1993;99:18-23.
5. Cazorla M, Hernandez L, Nadal A, et al. Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx. J Pathol. 1998;186:144-150.
6. Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M. Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer. 1999;80:366-1372.
7. Kurahara S, Shinohara M, Ikebe T, et al. Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: Correlations with tumor invasion and metastasis. Head Neck. 1999;21:627-638.
8. Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol. 2000;17:1099-1105.
9. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer, 2000;88:2001-2009.
10. Imanishi Y, Fujii M, Tokumaru Y, et al. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma. Hum Pathol. 2000;31:895-904.
11. Moncada S, Higgs A., The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
12. Lala PK, Orucevic A. Role of nitric oxide in tumor progression: Lesson from experimental tumors. Cancer Metast Rev. 1998;17:91-106.
13. Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst. 1998;90:587-596.
14. Jenkins DC, Charles IG, Thomsen LL, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA. 1995;92:4392-4396.
15. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol. 1999;155:1381-1390.
16. Murrell GAC, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun. 1995;206:15-21.
17. Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, Lala PK. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer. 1999;81:889-896.
18. Watling DL, Gown AM, Coltrera MD. Overexpression of p53 in head and neck cancer. Head Neck. 1992;14:437-444.
19. Maestro R, Dolcetti R, Gasparotto D, et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene. 1992;7:1159-1166.
20. Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS, Gluckman JL. The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1993;119:1118-1122.
21. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous turnouts. Nature. 1992;356:215-221.
22. Donehower LA, Godley LA, Aldaz CM, et al. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 1995;9:882-895.
23. Barak Y, Juven T, Haffner R, Oren M. Mdm2 expression is induced by wild type p53 activity. EMBO J. 1993;12:461-468.
24. Ginsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA. 1991;88:9979-9983.
25. Deb SP, Munoz RM, Brown DR, Subler MA, Deb S. Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene. 1994;9:1341-1349.
26. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev. 1996;10:1054-1072.
27. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
28. Gallo O, Sardi I, Pepe G, et al. Multiple primary tumors of the upper aerodigestive tract: Is there a role for constitutional mutations in the p53 gene? Int J Cancer. 1999;82:180-186.
29. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 1999;189:300-308.
30. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg. 2000;87:1215-1221.
31. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481-490.
32. Kurizaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep. 1998;5:673-677.
33. Ziche M, Parenti A, Ledda F, et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res. 1997;80:845-852.
34. Ziche M, Morbidelli L, Chouduri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625-2634.
35. Fukumura D, Jain RK. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metast Rev. 1998;17:77-89.
36. Sun Y, Cheung JM, Martel-Pelletier J, et al. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem. 2000;275:11327-11332.
37. Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J Biol Chem. 1999;274:11535-11540.
38. Ozdemir E, Kakehi Y, Okuno H, Habuchi T, Okada Y, Yoshida O. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas. J Urol. 1997;158:206-211.
39. Ioachim EE, Athanassiadou SE, Kamina S, Carassavoglou K, Agnantis NJ. Matrix metalloproteinase expression in human breast cancer: An immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative activity. Anticancer Res. 1998;18:1665-1770.
40. Ambs S, Ogunfusika MO, Merriam GW, Bennet WP, Billar TR, Harris CC. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci USA. 1998;95:8823-8828.
41. Esteve A, Lehman T, Jiang W, et al. Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinog. 1993;8:306-311.
42. Grandis JR, Zeng Q, Drenning SD, Tweardy DJ. Normalization of EGFR mRNA levels following restoration of wild-type p55 in a head and neck squamous cell line. Int J Oncol. 1998;13:375-378.
43. Shima I, Sasaguri Y, Kusukawa J, et al. Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. Br J Cancer. 1993;67:721-727.
44. O-Charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer. 2000;86:307-317.